Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Bristol-Myers Squibb Co trades at $57.56 (market cap $116.30B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.09. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| BMY | VWO | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $61.24 |
52-Week Low | $42.60 | $49.54 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
VWO, the Vanguard FTSE Emerging Markets ETF, trades at $58.79, down 1.84% on the day amid a bearish technical signal. The fund's key financial ratios are not available in the data, but recent news highlights its low expense ratio of 0.06% and focus on emerging markets excluding South Korea, which has impacted performance relative to peers. Technical indicators show mixed signals with neutral oscillators and bearish moving averages.
The outlook for VWO is influenced by emerging market flows and geopolitical factors, with opportunities in diversification away from U.S. stocks but risks from China's economic drag and expense ratio comparisons with competitors like EEM. Investor sentiment is cautious due to regional tensions and allocation debates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
